<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270554</url>
  </required_header>
  <id_info>
    <org_study_id>DP-Study 1401</org_study_id>
    <nct_id>NCT02270554</nct_id>
  </id_info>
  <brief_title>A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy</brief_title>
  <official_title>A Prospective, Multi-center Investigation of Impact of the Endo GIA Reinforced Reload With Tri-Staple Technology During Distal Pancreatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wakayama Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate if the Endo GIA Reinforced Reload with Tri-Staple
      Technology reduce incidence of pancreatic fistula (ISGPF grade B and C) after distal
      pancreatectomy by a prospective, multi-center trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reducing the incidence of pancreatic fistula is the most important issue in pancreatectomy.
      There is no certain view on the pancreatic resection method to reduce pancreatic fistula in
      distal pancreatectomy.This study will be conducted to scientifically investigate the impact
      of Endo GIA Reinforced Reload with Tri-Staple Technology in distal pancreatectomy. The aim of
      this study is to evaluate if the Endo GIA Reinforced Reload with Tri-Staple Technology reduce
      incidence of pancreatic fistula (ISGPF grade B and C) after distal pancreatectomy by a
      prospective, multi-center trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pancreatic fistula grade B/C</measure>
    <time_frame>Ninety days after operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of pancreatic fistula defined by ISGPF classification</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pancreatic fistula grade C defined by ISGPF classification</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intraabdominal bleeding</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital stay</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostasis condition of staple line</measure>
    <time_frame>during operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malformationof staple line Malformationof staple line Malformationof staple line Malformationof staple line Malformationof staple line</measure>
    <time_frame>during operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Period of drain insertion</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Damage of pancreatic stump</measure>
    <time_frame>during operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of additional suture of pancreatic stump</measure>
    <time_frame>during operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma</measure>
    <time_frame>Ninety days after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Reinforced staple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endo GIA Reinforced Reload with Tri-Staple technology</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endo GIA Reinforced Reload with Tri-Staple technology</intervention_name>
    <description>Device:Endo GIA Reinforced Reload with Tri-Staple technology</description>
    <arm_group_label>Reinforced staple</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. disease of pancreatic body and tail

          2. PS (ECOG Performance Status Scale)0-1

          3. Age: 20 years or older

          4. distant metastases are not diagnosed preoperatively. Eligible for this clinical study
             when only distal pancreatectomy contributes to the favorable prognosis even if
             patients with pancreatic neuroendocrine cancer have the liver metastasis

          5. Patients who can provide written informed consent

        Exclusion Criteria:

          1. Patients with severe ischemic cardiac disease

          2. Patients with severe liver cirrhosis or active hepatitis

          3. Patients with respiratory illness that requires oxygen administration

          4. Patients with chronic renal failure requiring dialysis

          5. Patients requiring other organ resection

          6. Patients who are unfit for the study as determined by the attending physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroki Yamaue, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wakayama Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University</name>
      <address>
        <city>Hirakata, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University</name>
      <address>
        <city>Kashihara, Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University</name>
      <address>
        <city>Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University</name>
      <address>
        <city>Sayama, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wakayama Medical University</investigator_affiliation>
    <investigator_full_name>Hiroki Yamaue</investigator_full_name>
    <investigator_title>Second Deaprtment of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

